Connection

NICOLA HANANIA to Pneumonia

This is a "connection" page, showing publications NICOLA HANANIA has written about Pneumonia.
Connection Strength

1.830
  1. Impact of antiviral therapy on short- and long-term outcomes of patients with chronic obstructive pulmonary disease after influenza infection. Influenza Other Respir Viruses. 2023 12; 17(12):e13231.
    View in: PubMed
    Score: 0.688
  2. Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol. 2019 08; 19(4):379-386.
    View in: PubMed
    Score: 0.509
  3. Targeting airway inflammation in asthma: current and future therapies. Chest. 2008 Apr; 133(4):989-98.
    View in: PubMed
    Score: 0.232
  4. The potential role of natural agents in treatment of airway inflammation. Ther Adv Respir Dis. 2007 Dec; 1(2):105-20.
    View in: PubMed
    Score: 0.227
  5. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan; 12(1):27-34.
    View in: PubMed
    Score: 0.093
  6. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May; 1(3):210-23.
    View in: PubMed
    Score: 0.082
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.